Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts

References

• Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010; 28:3994 - 4005
   PubMed Web of Science ®Google Scholar
• McClune AC, Tong MJ. Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis 2010; 14:461 - 476
   PubMed Web of Science ®Google Scholar
• Manizate F, Hiotis SP, Labow D, Roayaie S, Schwartz M. Liver functional reserve estimation: state of the art and relevance to local treatments. Oncology 2010; 78:131 - 134
   PubMed Web of Science ®Google Scholar
• Thomas MB, O'Beirne JP, Furuse J, Chan AT, Abou-Alfa G, Johnson P. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol 2008; 15:1008 - 1014
   PubMed Web of Science ®Google Scholar
• Hopfner M, Schuppan D, Scherubl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 2008; 14:1 - 14
   PubMed Web of Science ®Google Scholar
• Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010; 29:4989 - 5005
   PubMed Web of Science ®Google Scholar
• Yau T, Chan P, Epstein R, Poon RT. Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int 2009; 29:10 - 17
   PubMed Web of Science ®Google Scholar
• Zhu AX, Clark JW. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy. Oncologist 2009; 14:67 - 69
   PubMed Web of Science ®Google Scholar
• Carr BI, Carroll S, Muszbek N, Gondek K. Economic evaluation of sorafenib in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 2010; 25:1739 - 1746
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, et al. Doxorubicin plus sorafenib vs. doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. Jama 2010; 304:2154 - 2160
   PubMed Web of Science ®Google Scholar
• Bartke N, Hannun YA. Bioactive sphingolipids: metabolism and function. J Lipid Res 2009; 50:91 - 96
   PubMed Web of Science ®Google Scholar
• Meacham WD, Antoon JW, Burow ME, Struckhoff AP, Beckman BS. Sphingolipids as determinants of apoptosis and chemoresistance in the MCF-7 cell model system. Exp Biol Med (Maywood) 2009; 234:1253 - 1263
   Google Scholar
• Ozbayraktar FB, Ulgen KO. Molecular facets of sphingolipids: mediators of diseases. Biotechnol J 2009; 4:1028 - 1041
   PubMedGoogle Scholar
• Dumitru CA, Weller M, Gulbins E. Ceramide metabolism determines glioma cell resistance to chemotherapy. J Cell Physiol 2009; 221:688 - 695
   PubMed Web of Science ®Google Scholar
• Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta 2006; 1758:2016 - 2026
   PubMed Web of Science ®Google Scholar
• Lavieu G, Scarlatti F, Sala G, Levade T, Ghidoni R, Botti J, et al. Is autophagy the key mechanism by which the sphingolipid rheostat controls the cell fate decision?. Autophagy 2007; 3:45 - 47
   PubMed Web of Science ®Google Scholar
• Maceyka M, Payne SG, Milstien S, Spiegel S. Sphingosine kinase, sphingosine-1-phosphate, apoptosis. Biochim Biophys Acta 2002; 1585:193 - 201
   PubMed Web of Science ®Google Scholar
• Holman DH, Turner LS, El-Zawahry A, Elojeimy S, Liu X, Bielawski J, et al. Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Cancer Chemother Pharmacol 2008; 61:231 - 242
   PubMed Web of Science ®Google Scholar
• Chan SY, Hilchie AL, Brown MG, Anderson R, Hoskin DW. Apoptosis induced by intracellular ceramide accumulation in MDA-MB-435 breast carcinoma cells is dependent on the generation of reactive oxygen species. Exp Mol Pathol 2007; 82:1 - 11
   PubMed Web of Science ®Google Scholar
• French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003; 63:5962 - 5969
   PubMed Web of Science ®Google Scholar
• French KJ, Zhuang Y, Maines LW, Gao P, Wang W, Beljanski V, et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 2010; 333:129 - 139
   PubMed Web of Science ®Google Scholar
• Taha TA, Hannun YA, Obeid LM. Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol 2006; 39:113 - 131
   PubMedGoogle Scholar
• Beljanski V, Knaak C, Smith CD. A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J Pharmacol Exp Ther 2010; 333:454 - 464
   Google Scholar
• Beljanski V, Knaak C, Zhuang Y, Smith CD. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest New Drugs 2010; In press
   PubMed Web of Science ®Google Scholar
• Tafani M, Schito L, Anwar T, Indelicato M, Sale P, Di Vito M, et al. Induction of autophagic cell death by a novel molecule is increased by hypoxia. Autophagy 2008; 4:1042 - 1053
   PubMed Web of Science ®Google Scholar
• Park MA, Zhang G, Martin AP, Hamed H, Mitchell C, Hylemon PB, et al. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther 2008; 7:1648 - 1662
   PubMed Web of Science ®Google Scholar
• Kharel Y, Lee S, Snyder AH, Sheasley-O'neill SL, Morris MA, Setiady Y, et al. Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J Biol Chem 2005; 280:36865 - 36872
   PubMed Web of Science ®Google Scholar
• Josephs DH, Ross PJ. Sorafenib in hepatocellular carcinoma. Br J Hosp Med (Lond) 71:451 - 456
   PubMed Web of Science ®Google Scholar
• Lekili M, Muezzinoglu T, Nese N, Temeltas G. Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation. J Chin Med Assoc 73:262 - 264
   PubMed Web of Science ®Google Scholar
• Smit EF, Dingemans AM, Thunnissen FB, Hochstenbach MM, van Suylen RJ, Postmus PE. Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report. J Thorac Oncol 5:719 - 720
   PubMed Web of Science ®Google Scholar
• Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 2005; 41:773 - 784
   PubMed Web of Science ®Google Scholar
• Hasskarl J. Sorafenib. Recent Results Cancer Res 2010; 184:61 - 70
   PubMedGoogle Scholar
• Siskind LJ, Mullen TD, Romero Rosales K, Clarke CJ, Hernandez-Corbacho MJ, Edinger AL, et al. The BCL-2 protein BAK is required for long-chain ceramide generation during apoptosis. J Biol Chem 2010; 285:11818 - 11826
   PubMed Web of Science ®Google Scholar
• Edinger AL, Thompson CB. Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 2004; 16:663 - 669
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70:440 - 446
   PubMed Web of Science ®Google Scholar
• Ma Y, Wang J, Liu L, Zhu H, Chen X, Pan S, et al. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: Role of Akt and nuclear factorkappaB. Cancer Lett 2010;
   Web of Science ®Google Scholar
• He X, Huang CL, Schuchman EH. Quantitative analysis of sphingosine-1-phosphate by HPLC after napthalene-2,3-dicarboxaldehyde (NDA) derivatization. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:983 - 990
   PubMed Web of Science ®Google Scholar